New! Chronic Kidney Disease in Adults: Assessment and Management
New! KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
New! KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
New! GUIDELINE 11: Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD
New! Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry
New! Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF
New! Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
New! EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot)
New! EuroHeart Failure Survey II (EHFS II): A Survey on Hospitalized Acute Heart Failure Patients: Description of Population
New! The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators
New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer
New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
New! Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-angiotensin-aldosterone System Inhibitors
New! Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes
New! Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer
New! A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia
New! Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study
New! Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN
New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
New! Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project
New! Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
New! Mechanisms of Progression and Regression of Renal Lesions of Chronic Nephropathies and Diabetes
New! Iron Deficiency in Heart Failture: Looking Beyond Anaemia
New! Iron Deficiency and Heart Failure: Diagnostic Dilemmas and Therapeutic Perspectives
New! Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It
New! Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial
New! Iron Deficiency in 78 805 People Admitted with Heart Failure Across England: A Retrospective Cohort Study
New! Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure
New! Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial
New! The Hepcidin Circuits Act: Balancing Iron and Inflammation
New! Iron Deficiency in Heart Failure
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018
Expert Consensus Document on the Management of Hyperkalaemia in Patients with Cardiovascular Disease Treated with Renin Angiotensin Aldosterone System Inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
New! Chronic Kidney Disease in Adults: Assessment and Management
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
New! KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
New! KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
New! GUIDELINE 11: Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD
New! Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes
Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients with Heart Failure with Reduced Ejection Fraction: A Comparative Analysis of Three Randomised Controlled Trials
New! Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry
Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure Registry
Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry
Association Between Enrolment in a Heart Failure Quality Registry and Subsequent Mortality—A Nationwide Cohort Study
New! Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year Follow-up Outcomes and Differences Across Regions
Physicians' Adherence to Guideline-recommended Medications in Heart Failure with Reduced Ejection Fraction: Data from the QUALIFY Global Survey
New! Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
New! EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot)
Efficacy and Safety of Exercise Training in Patients with Chronic Heart Failure: HF-ACTION Randomized Controlled Trial.
Use of Aldosterone Antagonists in Heart Failure
Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings from OPTIMIZE-HF
Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings from IMPROVE HF
New! EuroHeart Failure Survey II (EHFS II): A Survey on Hospitalized Acute Heart Failure Patients: Description of Population
New! The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators
Unravelling the Interplay Between Hyperkalaemia, Renin-angiotensin-aldosterone Inhibitor Use and Clinical Outcomes: Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
Association Between Potassium Level and Outcomes in Heart Failure with Reduced Ejection Fraction: A Cohort Study from the Swedish Heart Failure Registry
Cardiovascular Risk Associated with Serum Potassium in the Context of Mineralocorticoid Receptor Antagonist Use in Patients with Heart Failure and Left Ventricular Dysfunction
New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review
Daily Home Monitoring of Potassium, Creatinine, and Estimated Plasma Volume in Heart Failure Post-discharge.
Patiromer Sorbitex Calcium for Hyperkalaemia
Recurrent Hyperkalaemia Management and Use of Renin–angiotensin–aldosterone System Inhibitors: A European Multi-national Targeted Chart Review
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors
Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN
New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
Potassium and the Use of Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data From BIOSTAT-CHF
Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project
Hyperkalemia in Heart Failure
Effect of Patiromer on Serum Potassium Level in Patients with Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Maintenance of Serum Potassium with Sodium Zirconium Cyclosilicate (ZS-9) in Heart Failure Patients: Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
New! Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-angiotensin-aldosterone System Inhibitors
Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients with Hyperkalemia: The HARMONIZE Randomized Clinical Trial
New! Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes
New! Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
New! Management of Hyperkalaemia in Acute Kidney Injury in a Heart Failure Patient with Patiromer
New! A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia
New! Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study
New! Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN
New! Incidence, Predictors and CLINICAL MANAGEMENT of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
New! Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project
New! Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
New! Mechanisms of Progression and Regression of Renal Lesions of Chronic Nephropathies and Diabetes
New! Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial
New! Iron Deficiency in 78 805 People Admitted with Heart Failure Across England: A Retrospective Cohort Study
Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction
New! Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure
Iron Deficiency in Heart Failure: An Overview
Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient Data Meta-Analysis
Screening, Diagnosis and Treatment of Iron Deficiency in Chronic Heart Failure: Putting the 2016 European Society of Cardiology Heart Failure Guidelines into Clinical Practice
New! Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency
New! Iron Deficiency in Heart Failture: Looking Beyond Anaemia
Beneficial Effects of Long-Term Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency
High Prevalence of Iron Deficiency in Patients with Acute Decompensated Heart Failure
New! Iron Deficiency and Heart Failure: Diagnostic Dilemmas and Therapeutic Perspectives
Iron Deficiency in Chronic Heart Failure: An International Pooled Analysis
Iron Deficiency Is a Key Determinant of Health-Related Quality of Life in Patients with Chronic Heart Failure Regardless of Anaemia Status
Iron Status in Patients with Chronic Heart Failure
Iron Deficiency Predicts Impaired Exercise Capacity in Patients with Systolic Chronic Heart Failure
New! The Hepcidin Circuits Act: Balancing Iron and Inflammation
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Balancing RAASi Therapy and Potassium: Understanding How it Works
Das Gleichgewicht zwischen RAASi-Therapie und Kalium: Die Wirkmechanismen
Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency
New! Common Misconceptions About Iron Deficiency in Heart Failure and What to Do About It
Don’t Be Fooled: It’s Iron Deficiency, Not Just Anemia
Examining Heart Failure Management: Can We Be Doing Better?
Iron Deficiency and Anemia: What’s the Difference?
New! Iron Deficiency in Heart Failure
Mechanismen bei Herzinsuffizienz: Die Auswirkungen von Eisenmangel
Management of Heart Failure: Time to Consider New Options?
Potassium Binders in Heart Failure: Who, When, and How
Potassium Management
Potassium Management in Patients at Risk for Hyperkalemia
AHA Heart Failure Tools and Resources for Patients
Heart Foundation of Australia Heart Failure Resources for Patients
ESC Heartfailurematters.org Patient Education Website
Potassium and Heart Failure